Sex correlates with differences in long-term outcome in chronic myeloid leukaemia patients treated with imatinib

Br J Haematol. 2016 Jun;173(6):945-6. doi: 10.1111/bjh.13649. Epub 2015 Aug 25.

Authors

Massimo Breccia¹, Gioia Colafigli², Matteo Molica², Federico De Angelis², Luisa Quattrocchi², Roberto Latagliata², Marco Mancini², Daniela Diverio², Giuliana Alimena²

Affiliations

¹ Department of Cellular Biotechnologies and Haematology, Sapienza University, Rome, Italy. breccia@bce.uniroma1.it.
² Department of Cellular Biotechnologies and Haematology, Sapienza University, Rome, Italy.

PMID: 26304741
DOI: 10.1111/bjh.13649

No abstract available

Keywords: chronic myeloid leukaemia; imatinib; prognosis; sex.

Publication types

Letter

MeSH terms

Adult
Aged
Aged, 80 and over
Antineoplastic Agents / therapeutic use*
Female
Humans
Imatinib Mesylate / therapeutic use*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / mortality
Male
Middle Aged
Sex Factors*
Survival Analysis
Time Factors
Treatment Outcome
Young Adult

Substances

Antineoplastic Agents
Imatinib Mesylate